(Q36407249)

14 August 2017

1 reference

title

In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer (English)

1 reference

14 August 2017

Hongsheng Xie

1

1 reference

PubMed ID

16503736

14 August 2017

Walter A Blättler

series ordinal

2

1 reference

PubMed ID

16503736

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

281-291

1 reference

14 August 2017

3

1 reference

Progress in immunoconjugate cancer therapeutics

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Humanization of murine monoclonal antibodies through variable domain resurfacing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Targeted toxin therapy for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Drug delivery systems: entering the mainstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Scavenger endothelial cells of vertebrates: a nonperipheral leukocyte system for high-capacity elimination of waste macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Antibody-targeted drugs for the therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

Dose scheduling--Herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.281

21 January 2018

Identifiers

DOI

10.1517/14712598.6.3.281

1 reference

14 August 2017

1 reference

PubMed ID

16503736